Galera Therapeutics (GRTX) Competitors $0.03 +0.00 (+5.69%) As of 03:12 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. JBIO, SLXN, CELZ, INAB, SBFM, PPBT, APLM, PMCB, BCLI, and MYNZShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Jade Biosciences (JBIO), Silexion Therapeutics (SLXN), Creative Medical Technology (CELZ), IN8bio (INAB), Sunshine Biopharma (SBFM), Purple Biotech (PPBT), Apollomics (APLM), Nuvilex (PMCB), Brainstorm Cell Therapeutics (BCLI), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors Jade Biosciences Silexion Therapeutics Creative Medical Technology IN8bio Sunshine Biopharma Purple Biotech Apollomics Nuvilex Brainstorm Cell Therapeutics Mainz Biomed Galera Therapeutics (NASDAQ:GRTX) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Which has more volatility and risk, GRTX or JBIO? Galera Therapeutics has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, Jade Biosciences has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Is GRTX or JBIO more profitable? Galera Therapeutics' return on equity of 0.00% beat Jade Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Jade Biosciences N/A -60.01%-54.32% Do insiders & institutionals hold more shares of GRTX or JBIO? 50.8% of Galera Therapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by insiders. Comparatively, 24.9% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate GRTX or JBIO? Jade Biosciences has a consensus target price of $15.00, suggesting a potential upside of 118.02%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Jade Biosciences is more favorable than Galera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Jade Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, GRTX or JBIO? Jade Biosciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.26-0.10Jade BiosciencesN/AN/A-$69.63M-$59.65-0.12 Does the media refer more to GRTX or JBIO? In the previous week, Jade Biosciences had 2 more articles in the media than Galera Therapeutics. MarketBeat recorded 2 mentions for Jade Biosciences and 0 mentions for Galera Therapeutics. Jade Biosciences' average media sentiment score of 1.89 beat Galera Therapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Galera Therapeutics Neutral Jade Biosciences Very Positive SummaryJade Biosciences beats Galera Therapeutics on 7 of the 13 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.96M$782.13M$5.59B$9.53BDividend YieldN/A4.84%4.71%4.03%P/E Ratio-0.071.3627.9619.93Price / SalesN/A24.78389.5465.88Price / CashN/A19.5636.3258.75Price / Book-0.016.688.375.77Net Income-$59.08M-$4.52M$3.25B$259.10M7 Day PerformanceN/A-1.96%-2.50%-3.41%1 Month PerformanceN/A5.23%7.98%8.53%1 Year PerformanceN/A12.18%34.65%15.75% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.03+5.7%N/A-81.1%$1.96MN/A-0.0730Gap UpJBIOJade Biosciences2.3868 of 5 stars$8.80+1.3%$15.00+70.5%N/A$7.39MN/A-0.1520SLXNSilexion TherapeuticsN/A$0.85+2.6%$5.00+491.0%N/A$7.35MN/A0.00N/AStock SplitCELZCreative Medical Technology1.3473 of 5 stars$2.78+1.5%N/A-26.4%$7.19M$14K-0.735INABIN8bio3.5006 of 5 stars$2.36+2.6%$180.00+7,527.1%-91.2%$7.12MN/A-0.1720SBFMSunshine Biopharma2.9274 of 5 stars$1.59+1.6%$15.00+846.4%+407.1%$7.11M$34.87M-0.013PPBTPurple Biotech2.2553 of 5 stars$2.73-1.8%$33.00+1,108.8%N/A$7.07MN/A-1.0420APLMApollomics1.0327 of 5 stars$6.38-9.8%N/A-70.7%$7.01M$1.49M0.0045Gap UpPMCBNuvilex2.7591 of 5 stars$1.01+1.5%N/A-49.0%$6.93MN/A1.364Gap DownBCLIBrainstorm Cell Therapeutics1.1424 of 5 stars$0.70-5.5%N/A-85.4%$6.88MN/A-0.2140Gap DownMYNZMainz Biomed3.0493 of 5 stars$1.99-6.4%$14.00+602.1%-86.7%$6.74M$890K-0.0330 Related Companies and Tools Related Companies JBIO Competitors SLXN Competitors CELZ Competitors INAB Competitors SBFM Competitors PPBT Competitors APLM Competitors PMCB Competitors BCLI Competitors MYNZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
